Chugai Pharmaceutical Co., Ltd.
TSE-4519
Company Overview
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
Name
Chugai Pharmaceutical Co., Ltd.
CEO
Dr. Osamu Okuda
Website
www.chugai-pharm.co.jp
Sector
Pharmaceuticals
Year Founded
1925
Profile
Market Cap
¥10.82T
EV
¥10.01T
Shares Out
1,645.47M
Revenue
¥1,084.57B
Employees
7,604
Margins
Gross
69.46%
EBITDA
47.77%
Operating
44.85%
Pre-Tax
45.07%
Net
32.74%
FCF
24.66%
Returns (5Yr Avg)
ROA
19.84%
ROTA
25.06%
ROE
24.52%
ROCE
33.25%
ROIC
32.93%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
¥6,663.33
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
¥815.66B
Net Debt
-¥815.66B
Debt/Equity
0.01
EBIT/Interest
40,538.25
Growth (CAGR)
Rev 3Yr
10.26%
Rev 5Yr
12.02%
Rev 10Yr
9.33%
Dil EPS 3Yr
15.46%
Dil EPS 5Yr
25.69%
Dil EPS 10Yr
20.43%
Rev Fwd 2Yr
1.82%
EBITDA Fwd 2Yr
6.94%
EPS Fwd 2Yr
8.61%
EPS LT Growth Est
6.21%
Dividends
Yield
—
Payout
37.54%
DPS
¥81
DPS Growth 3Yr
10.52%
DPS Growth 5Yr
18.73%
DPS Growth 10Yr
18.37%
DPS Growth Fwd 2Yr
6.56%